These transgenic mice express a mutant form of human myotilin (MYOT) directed by the human skeletal muscle alpha 1 actin (ACTA1) promoter in skeletal muscle.
Michael A. Hauser, Duke University Medical Center
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
Mice hemizygous for this TgT57I transgene are viable and fertile, with expression of a mutant form of human myotilin (MYOT harboring a T57I point mutation) directed by the human skeletal muscle alpha 1 actin (ACTA1) promoter. RT-PCR reveals transgene expression is specific to skeletal muscle. Mutant mice exhibit progressive muscle pathology. Small myofibrillar aggregates are observed in 2 week old mutant transgenic mice. By age 12 months, aggregates are predominantly found in the quadriceps and triceps (upper forelimb and hindlimb muscles), with the number of affected fibers and pathology increasing with age. Sarcolemmal damage is also observed. Fibrosis, tubular aggregation and adipose infiltration is observed in older transgenic mice. Muscle tissue of the diaphragm, soleus, biceps and ulnar do not form aggregates. Ultrastructural examination of muscle tissue from transgenic mice reveals sarcomeric abnormalities, such as Z-disc streaming. Isolated whole intact extensor digitorum longus muscle exhibits contractile dysfunction with reduced muscle mass and diminished specific maximum force. These mice recapitulate key features of human myotilinopathies and provide a model for studying the underlying mechanism of rela ted diseases such as limb-girdle muscular dystrophy type 1A (LGMD1A), myofibrillar myopathy (MFM), and spheroid body myopathy (SBM). Analysis of transgene inheritance patterns at The Jackson Laboratory colony and the donating investigator's colony suggest that the transgene integrated on the X chromosome. The effects (if any) of X chromosome inactivation in female hemizygotes are not yet characterized (October 2007).
A transgenic construct containing the human myotilin gene, MYOT with a T57I point mutation, a c-myc (Myc) epitope tag, and SV40 polyadenylation site sequence under the control of the human skeletal muscle alpha 1 actin, ACTA1, promoter was injected into fertilized B6SJLF2 mouse eggs. Founder line 71 was established. Founder animals were backcrossed onto the C57BL/6J background for 9 generations by the donating investigator. Analysis of transgene inheritance patterns at The Jackson Laboratory colony and the donating investigator's colony suggest that the transgene integrated on the X chromosome (October 2007).
Expressed Gene | MYOT, myotilin, human |
---|---|
Site of Expression |
Allele Name | transgene insertion 71, Michael Hauser |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | Tg(ACTA1-MYOT)71Mah; Tg(HSA-MYOT)71Mah; TgT57I |
Gene Symbol and Name | Tg(ACTA1-MYOT*T57I)71Mah, transgene insertion 71, Michael Hauser |
Gene Synonym(s) | |
Promoter | ACTA1, actin, alpha 1, skeletal muscle, human |
Expressed Gene | MYOT, myotilin, human |
Strain of Origin | (C57BL/6 x SJL)F2 |
Chromosome | UN |
Molecular Note | The point mutation responsible for limb-girdle muscular dystrophy type 1A (LGMD1A) in a North American family - substitution of threonine for isoleucine at amino acid position 57 (T57I) of the protein - was introduced into the human myotilin cDNA. This mutant cDNA, comprising 1530 bp of coding sequence, 281 bp of 5' UTR and 485 bp of 3' UTR, with sequence encoding a MYC epitope tag inserted at the beginning of the coding region, was cloned into the HAS-VP1 expression vector downstream of nucleotides -2139 through +239 of the human actin, skeletal, alpha 1 gene followed by the splice acceptor from the SV40 P1 intron; two copies of the SV40 polyadenylation signal follow the 3'UTR of the cDNA. RT-PCR analysis of several tissues detected transgene-derived mRNA only in skeletal muscle, and immunoblot analysis with antibody against MYC demonstrated appropriate expression of the transgene product in multiple striated muscles. Immunohistologic examination of muscle sections revealed uniformity of expression in fibers within a muscle group and similarity of expression in slow, type I and in fast, type II fibers. Expression of the mutant human myotilin is 2.6-fold that of the endogenous mouse protein. |
Mutations Made By | Sean Garvey, Duke University Medical Center |
When maintaining a live colony, these mice are bred as hemizygotes. Analysis of transgene inheritance patterns at The Jackson Laboratory colony and the donating investigator's colony suggest that the transgene integrated on the X chromosome (October 2007).
When using the TgT57I mouse strain in a publication, please cite the originating article(s) and include JAX stock #006615 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(ACTA1-MYOT*T57I)71Mah |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-MYOT*T57I)71Mah/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-MYOT*T57I)71Mah/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-MYOT*T57I)71Mah/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-MYOT*T57I)71Mah/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.